Therapy of psychological and behavioral symptoms in dementia;Therapie von psychischen und Verhaltenssymptomen bei Demenz

Nervenarzt

Volumn 81, Issue 7, 2010, Pages 815-822

  Jessen, F ^a   Spottke, A ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Behavioral and psychological symptoms in dementia; Delirium; Guidelines; Pharmacological treatment; Psychosocial interventions

Indexed keywords

BEHAVIOR DISORDER; DEMENTIA; GERMANY; HUMAN; MEDICAL SOCIETY; NEUROPSYCHIATRY; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; REVIEW;

DEMENTIA; GERMANY; HUMANS; MENTAL DISORDERS; NEUROPROTECTIVE AGENTS; PRACTICE GUIDELINES AS TOPIC; PSYCHOTHERAPY;

EID: 77955585887     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-010-3002-z     Document Type: Review

References (46)

1. Aalten P, Verhey FR, Boziki M et al (2008) Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 25:1-8
2. Ballard C, Hanney ML, Theodoulou M et al (2009) The dementia antipsychotic withdrawal trial (DART-AD): Long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8:151-157
3. Ballard C, Lana MM, Theodoulou M et al (2008) A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 5:e76
4. Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev:CD003476
5. Birks J, Harvey RJ (2006) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev:CD001190
6. Bruce DG, Paley GA, Nichols P et al (2005) Physical disability contributes to caregiver stress in dementia caregivers. J Gerontol A Biol Sci Med Sci 60:345-349
7. Chew ML, Mulsant BH, Pollock BG et al (2008) Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 56:1333-1341
8. Vugt De ME, Stevens F, Aalten P, et al. (2005) A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr 17:577-589
9. Devanand DP, Marder K, Michaels KS et al (1998) A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 155:1512-1520
10. Douglas IJ, Smeeth L (2008) Exposure to antipsychotics and risk of stroke: Self controlled case series study. BMJ 337:1227
11. Dowling GA, Burr RL, Van Someren EJ et al (2008) Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. J Am Geriatr Soc 56:239-246
12. Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351:2509-2518
13. Fossey J, Ballard C, Juszczak E et al (2006) Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: Cluster randomised trial. BMJ 332:756-761
14. Gill SS, Seitz DP (2007) Association of antipsychotics with mortality among elderly patients with dementia. Am J Geriatr Psychiatry 15:983-985
15. Herrmann N, Rabheru K, Wang J, Binder C (2005) Galantamine treatment of problematic behavior in Alzheimer disease: Post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 13:527-534
16. Howard RJ, Juszczak E, Ballard CG et al (2007) Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357:1382-1392
17. Inouye SK (2006) Delirium in older persons. N Engl J Med 354:1157-1165
18. Livingston G, Johnston K, Katona C et al (2005) Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 162:1996-2021
19. Lonergan 2007 Cochrane Database Syst Rev CD005594
20. Lonergan E, Luxenberg J (2009) Valproate preparations for agitation in dementia. Cochrane Database Syst Rev:CD003945
21. Lonergan E, Luxenberg J, Colford J (2002) Haloperidol for agitation in dementia. Cochrane Database Syst Rev:CD002852
22. Loy C, Schneider L (2006) Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev:CD001747
23. McCurry SM, Gibbons LE, Logsdon RG et al (2005) Nighttime insomnia treatment and education for Alzheimer's disease: A randomized, control ed trial. J Am Geriatr Soc 53:793-802
24. McKeith I, Del Ser T, Spano P et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 356:2031-2036
25. McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev:CD003154
26. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: A multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
27. Nyth AL, Gottfries CG, Lyby K et al (1992) A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86:138-145
28. Olin JT, Fox LS, Pawluczyk S et al (2001) A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 9:400-405
29. Ozbolt LB, Paniagua MA, Kaiser RM (2008) Atypical antipsychotics for the treatment of delirious elders. J Am Med Dir Assoc 9:18-28
30. Pollock BG, Mulsant BH, Rosen J et al (2007) A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15:942-952
31. Pollock BG, Mulsant BH, Rosen J et al (2002) Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 159:460-465
32. Rabinowitz J, Katz I, De Deyn PP et al (2007) Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone. Int Psychogeriatr 19:227-240
33. Riemersma-van der Lek RF, Swaab DF, Twisk J et al (2008) Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: A randomized controlled trial. JAMA 299:2642-2655
34. Robert PH, Verhey FR, Byrne EJ et al (2005) Grouping for behavioral and psychological symptoms in dementia: Clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry 20:490-496
35. Roth M, Mountjoy CQ, Amrein R (1996) Moclobemide in elderly patients with cognitive decline and depression: An international double-blind, placebo-controlled trial. Br J Psychiatry 168:149-157
36. Savva GM, Zaccai J, Matthews FE et al (2009) Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry 194:212-219
37. Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14:191-210
38. Serfaty M, Kennell-Webb S, Warner J et al (2002) Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. Int J Geriatr Psychiatry 17:1120-1127
39. Singer C, Tractenberg RE, Kaye J et al (2003) A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 26:893-901 (Pubitemid 39610638)
40. Tariot PN, Erb R, Podgorski CA et al (1998) Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155:54-61
41. Thompson S, Herrmann N, Rapoport MJ, Lanctot KL (2007) Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: A metaanalysis. Can J Psychiatry 52:248-255
42. Wang PS, Schneeweis S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353:2335-2341
43. Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies. Am J Psychiatry 164:1491-1498
44. Wilcock GK, Ballard CG, Cooper JA, Loft H (2008) Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: A pooled analysis of 3 studies. J Clin Psychiatry 69:341-348 (Pubitemid 351549385)
45. Wooltorton E (2004) Olanzapine (Zyprexa): Increased incidence of cerebrovascular events in dementia trials. CMAJ 170:1395
46. Wooltorton E (2002) Risperidone (Risperdal): Increased rate of cerebrovascular events in dementia trials. CMAJ 167:1269-1270